Literature DB >> 25006453

Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis.

Dhruv Nayyar1, Kavitha Muthiah2, Gayathri Kumarasinghe2, Ravin Hettiarachchi1, David Celermajer2, Eugene Kotlyar2, Anne Keogh2.   

Abstract

Despite currently available treatments, the prognoses of pulmonary arterial hypertension (PAH) and pulmonary capillary hemangiomatosis (PCH) remain poor. Platelet-derived growth factor and its receptor (PDGFR) have been implicated in the pathogenesis of pulmonary hypertension in PAH and PCH. Imatinib, a PDGFR antagonist, may be beneficial in the treatment of both conditions because of its potent antiproliferative effect. We report two cases that demonstrate the potential for safe and efficacious use of imatinib in PAH and PCH.

Entities:  

Year:  2014        PMID： 25006453      PMCID： PMC4070788          DOI： 10.1086/675996

Source DB:  PubMed          Journal:  Pulm Circ        ISSN： 2045-8932            Impact factor:   3.017


  18 in total

1.  Imatinib for the treatment of pulmonary arterial hypertension.

Authors:  Hossein A Ghofrani; Werner Seeger; Friedrich Grimminger
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

2.  Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.

Authors:  Karen C Patterson; Ariel Weissmann; Tahamtan Ahmadi; Harrison W Farber
Journal:  Ann Intern Med       Date:  2006-07-18       Impact factor: 25.391

Review 3.  Imatinib.

Authors:  Christine E de Kogel; Jan H M Schellens
Journal:  Oncologist       Date:  2007-12

4.  Reversal of experimental pulmonary hypertension by PDGF inhibition.

Authors:  Ralph Theo Schermuly; Eva Dony; Hossein Ardeschir Ghofrani; Soni Pullamsetti; Rajkumar Savai; Markus Roth; Akylbek Sydykov; Ying Ju Lai; Norbert Weissmann; Werner Seeger; Friedrich Grimminger
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 5.  Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Authors:  Caroline Robert; Jean-Charles Soria; Alain Spatz; Axel Le Cesne; David Malka; Patricia Pautier; Janine Wechsler; Catherine Lhomme; Bernard Escudier; Valérie Boige; Jean-Pierre Armand; Thierry Le Chevalier
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

6.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Authors:  Ramzi Dagher; Martin Cohen; Gene Williams; Mark Rothmann; Jogarao Gobburu; Gabriel Robbie; Atiqur Rahman; Gang Chen; Ann Staten; Donna Griebel; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

7.  Platelet-derived growth factor is increased in pulmonary capillary hemangiomatosis.

Authors:  Adel M Assaad; Steven M Kawut; Selim M Arcasoy; Erika B Rosenzweig; Jessie S Wilt; Joshua R Sonett; Alain C Borczuk
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

8.  Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.

Authors:  Masaru Hatano; Atsushi Yao; Taro Shiga; Koichiro Kinugawa; Yasunobu Hirata; Ryozo Nagai
Journal:  Int Heart J       Date:  2010-07       Impact factor: 1.862

9.  Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

Authors:  Frédéric Perros; David Montani; Peter Dorfmüller; Ingrid Durand-Gasselin; Colas Tcherakian; Jérôme Le Pavec; Michel Mazmanian; Elie Fadel; Sacha Mussot; Olaf Mercier; Philippe Hervé; Dominique Emilie; Saadia Eddahibi; Gérald Simonneau; Rogério Souza; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2008-04-17       Impact factor: 21.405

10.  Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.

Authors:  Elizabeth Day; Beatrice Waters; Katrin Spiegel; Tanja Alnadaf; Paul W Manley; Elisabeth Buchdunger; Christoph Walker; Gabor Jarai
Journal:  Eur J Pharmacol       Date:  2008-10-11       Impact factor: 4.432
View more
  6 in total

1.  Pulmonary capillary hemangiomatosis: a case series and review of literature.

Authors:  Mahmoud Abdelnabi; Abdallah Almaghraby; Hoda Abdelgawad; Fatma Elkafrawy; Karim Ziada
Journal:  Am J Cardiovasc Dis       Date:  2021-04-15

2.  Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension.

Authors:  Kang Wu; Haiyang Tang; Ruizhu Lin; Shane G Carr; Ziyi Wang; Aleksandra Babicheva; Ramon J Ayon; Pritesh P Jain; Mingmei Xiong; Marisela Rodriguez; Shamin Rahimi; Francesca Balistrieri; Shayan Rahimi; Daniela Valdez-Jasso; Tatum S Simonson; Ankit A Desai; Joe G N Garcia; John Y-J Shyy; Patricia A Thistlethwaite; Jian Wang; Ayako Makino; Jason X-J Yuan
Journal:  Pulm Circ       Date:  2020-09-10       Impact factor: 3.017

3.  Pulmonary capillary hemangiomatosis: the role of invasive cardiopulmonary exercise testing.

Authors:  Hilary M DuBrock; Richard L Kradin; Josanna M Rodriguez-Lopez; Richard N Channick
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

4.  Features of radiological and physiological findings in pulmonary capillary hemangiomatosis: an updated pooled analysis of confirmed diagnostic cases.

Authors:  Rie Anazawa; Jiro Terada; Seiichiro Sakao; Ayako Shigeta; Nobuhiro Tanabe; Koichiro Tatsumi
Journal:  Pulm Circ       Date:  2019-12-27       Impact factor: 3.017

5.  Vasoproliferative process resembling pulmonary capillary hemangiomatosis in a cat.

Authors:  J A Jaffey; K J Williams; I Masseau; M Krueger; C Reinero
Journal:  BMC Vet Res       Date:  2017-03-20       Impact factor: 2.741

Review 6.  Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesis.

Authors:  Lijiang Ma; Ruijun Bao
Journal:  Appl Clin Genet       Date:  2015-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.